232 related articles for article (PubMed ID: 15272577)
41. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
[TBL] [Abstract][Full Text] [Related]
42. C-reactive protein in urologic cancers.
Huang J; Baum Y; Alemozaffar M; Ogan K; Harris W; Kucuk O; Master VA
Mol Aspects Med; 2015 Nov; 45():28-36. PubMed ID: 25936279
[TBL] [Abstract][Full Text] [Related]
43. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
44. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
[TBL] [Abstract][Full Text] [Related]
45. [Usefulness of tumor markers in the treatment of germ cell tumors].
Germá Lluch JR; García del Muro X; Galán MC
Arch Esp Urol; 2000; 53(6):460-8. PubMed ID: 11002513
[TBL] [Abstract][Full Text] [Related]
46. Tumor M2 pyruvate kinase in plasma of patients with urological tumors.
Roigas J; Schulze G; Raytarowski S; Jung K; Schnorr D; Loening SA
Tumour Biol; 2001; 22(5):282-5. PubMed ID: 11553857
[TBL] [Abstract][Full Text] [Related]
47. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.
Murphy G; Ragde H; Kenny G; Barren R; Erickson S; Tjoa B; Boynton A; Holmes E; Gilbaugh J; Douglas T
Anticancer Res; 1995; 15(4):1473-9. PubMed ID: 7544569
[TBL] [Abstract][Full Text] [Related]
48. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
[TBL] [Abstract][Full Text] [Related]
49. Interlaboratory surveys of the determination of tumour markers scatter and repeatability of the results.
Kruse R; Geilenkeuser WJ; Röhle G
Eur J Clin Chem Clin Biochem; 1993 Mar; 31(3):139-46. PubMed ID: 7683915
[TBL] [Abstract][Full Text] [Related]
50. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation.
Reiter MJ; Costello JE; Schwope RB; Lisanti CJ; Osswald MB
J Comput Assist Tomogr; 2015; 39(6):825-34. PubMed ID: 26248153
[TBL] [Abstract][Full Text] [Related]
51. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
52. Haemoglobin-F levels in urogenital cancers.
Müderrisoğlu C; Kansu E; Akdas A; Laleli Y; Firat D
Br J Urol; 1983 Jun; 55(3):264-7. PubMed ID: 6189544
[TBL] [Abstract][Full Text] [Related]
53. Utility of serum tumor markers during surveillance for stage I seminoma.
Vesprini D; Chung P; Tolan S; Gospodarowicz M; Jewett M; O'Malley M; Sweet J; Moore M; Panzarella T; Sturgeon J; Sugar L; Anson-Cartwright L; Warde P
Cancer; 2012 Nov; 118(21):5245-50. PubMed ID: 22517478
[TBL] [Abstract][Full Text] [Related]
54. Tumor markers in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):117-28. PubMed ID: 6170952
[TBL] [Abstract][Full Text] [Related]
55. GAD1 is a biomarker for benign and malignant prostatic tissue.
Jaraj SJ; Augsten M; Häggarth L; Wester K; Pontén F; Ostman A; Egevad L
Scand J Urol Nephrol; 2011 Feb; 45(1):39-45. PubMed ID: 21091088
[TBL] [Abstract][Full Text] [Related]
56. Precise prostate cancer diagnosis using fluorescent nanoprobes for detecting PSA and PSMA in serum.
Ouyang M; Jia M; Chang Z; Wang Y; Wang K; Gao X; Tang B
Chem Commun (Camb); 2024 May; 60(39):5181-5184. PubMed ID: 38647078
[TBL] [Abstract][Full Text] [Related]
57. The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma.
Chu DC; Chuang CK; Liou YF; Tzou RD; Lee HC; Sun CF
Ann N Y Acad Sci; 2004 Jun; 1022():157-62. PubMed ID: 15251956
[TBL] [Abstract][Full Text] [Related]
58. [The role of tumor markers in the treatment of germ cell tumor].
Niwakawa M; Tobisu K
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1159-65. PubMed ID: 11525037
[TBL] [Abstract][Full Text] [Related]
59. Re: Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.
Schatte EC; Lerner SP
J Urol; 2000 Nov; 164(5):1670. PubMed ID: 11203071
[No Abstract] [Full Text] [Related]
60. Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion.
de la Taille A; Cao Y; Sawczuk IS; Nozemu T; d'Agati V; McKiernan JM; Bagiella E; Buttyan R; Burchardt M; Olsson CA; Bander N; Katz AE
Cancer Detect Prev; 2000; 24(6):579-88. PubMed ID: 11198272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
